N/A
N=667
LINK: Aftercare Monitoring Project
Alcohol Dependence · Drug Dependence
Bottom Line
View on ClinicalTrials.gov: NCT00265512 ↗Enrolled (actual)
667
Serious AEs
22.8%
Results posted
Oct 2014
Primary outcome: Primary: Rates of Substance Use — 91.1; 88.0 percentage of days
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Telephone Case Monitoring (Behavioral); Continuing Care as Usual (Behavioral)
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- VA Office of Research and Development
- Primary completion
- Jun 2009
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Rates of Substance Use |
91.1; 88.0 | — |
| SECONDARY Psychiatric Symptoms |
47.22; 50.50; 49.76; 51.88; 48.79; 51.18 | — |
| SECONDARY Health Related Quality of Life |
45.64; 44.92; 44.54; 43.58; 43.37; 42.72 | — |
Summary
The prevalence of substance use disorders (SUD) in the VA is rising, making SUD(s) among the most commonly diagnosed disorders in the VA. A substantial body of data attests to the effectiveness of substance use disorder treatment; further the predictor most consistently associated with positive addiction treatment outcomes is duration. Despite the body of evidence supporting length of treatment as one of the stronger predictors of long-term SUD outcomes, only 36% of SUD treatment programs in the VA are meeting the continuing care performance criterion specified by the Office of Quality Performance. This randomized clinical trial investigates whether substance use disorder patients assigned to telephone case monitoring (TCM) for continuing care will do better than those attending face-to-face continuing care as usual (CCAU)(standard outpatient care).
Eligibility Criteria
Inclusion Criteria
Participants will be recruited from all patients who complete at least 14 days of intensive outpatient (IOP) substance use disorder treatment over an 18-month period in 2 VA IOP SUD programs.
Exclusion Criteria
Completion of less than 14 days of IOP treatment.
Data sourced from ClinicalTrials.gov (NCT00265512). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.